• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Telesis Bio Inc.

    11/8/24 8:23:25 AM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TBIO alert in real time by email
    SC 13G/A 1 sc13ga2.htm SCHEDULE 13G, AMENDMENT NO. 2



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

    Telesis Bio Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
     
    192003101
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:


    ☐
    Rule 13d-1(b)


    ☐
    Rule 13d-1(c)


    ☒
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    CUSIP No.: 192003101


    1.
    NAME OF REPORTING PERSON
     
    Danaher Corporation
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     
    (a)
    ☐
     
    (b)
    ☐
    3.
    SEC USE ONLY
     
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5.
    SOLE VOTING POWER
     
    0
    6.
    SHARED VOTING POWER
     
    0
    7. 
    SOLE DISPOSITIVE POWER
     
    0
    8.  
    SHARED DISPOSITIVE POWER
     
    0
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.0% 
    12.
    TYPE OF REPORTING PERSON
     
    CO 


    2


    CUSIP No.: 192003101


    1.
    NAME OF REPORTING PERSON
     
    Danaher Ventures LLC
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     
    (a)
    ☐
     
    (b)
    ☐
    3.
    SEC USE ONLY
     
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5.
    SOLE VOTING POWER
     
    0
    6.
    SHARED VOTING POWER
     
    0
    7. 
    SOLE DISPOSITIVE POWER
     
    0
    8.  
    SHARED DISPOSITIVE POWER
     
    0
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.0% 
    12.
    TYPE OF REPORTING PERSON
     
    OO 


    3

    Item 1.


    (a)
    Name of Issuer:

    The name of the issuer is Telesis Bio Inc. (the “Issuer”).


    (b)
    Address of Issuer’s Principal Executive Offices:

    The address of the Issuer’s principal executive offices is:

    Telesis Bio Inc.
    9535 Waples Street, Suite 100
    San Diego, CA 92121-2993

    Item 2.


    (a)
    Name of Person Filing:

    This schedule is filed by Danaher Corporation, a Delaware corporation (“Danaher”), and its subsidiary, Danaher Ventures LLC, a Delaware limited liability company (“DV”).  DV was formerly known as Danaher Innovation Center LLC prior to an internal restructuring that resulted in a change of its name. Danaher and DV are collectively referred to herein as the “Reporting Persons.”


    (b)
    Address of Principal Business Office:

    The address of the principal office of each of the Reporting Persons is:

    2200 Pennsylvania Avenue, NW
    Suite 800W
    Washington, DC 20037-1701


    (c)
    Citizenship:

    Danaher is a Delaware corporation.  DV is a Delaware limited liability company.


    (d)
    Title of Class of Securities:

    Common Stock, par value $0.0001 per share (the “Common Stock”)


    (e)
    CUSIP Number:

    192003101

    Item 3.
    Statement filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c).

    Not applicable.

    Item 4.
    Ownership.


    (a)
    Amount beneficially owned: See Item 9 of the cover page for each Reporting Person.
    4




    (b)
    Percent of class: See Item 11 of the cover page for each Reporting Person.


    (c) (i)           Sole power to vote or direct the vote:

    See Item 5 of the cover page for each Reporting Person.


    (ii)
    Shared power to vote or direct the vote:

    See Item 6 of the cover page for each Reporting Person.


    (iii)
    Sole power to dispose or direct the disposition:

    See Item 7 of the cover page for each Reporting Person.


    (iv)
    Shared power to dispose or direct the disposition:

    See Item 8 of the cover page for each Reporting Person.

    Item 5.
    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group.

    Not applicable.

    Item 9.
    Notice of Dissolution of Group.

    Not applicable.

    Item 10.
    Certifications.

    Not applicable.


    5

    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Dated: November 8, 2024

     
     
    DANAHER CORPORATION
       
       
     
    By:
    /s/ Jose-Carlos Gutierrez-Ramos
     
    Name:  
    Jose-Carlos Gutierrez-Ramos
     
    Title:
    Senior Vice President and Chief Science Officer
       
     
    DANAHER VENTURES LLC
       
       
     
    By:
    /s/ Jose-Carlos Gutierrez-Ramos
     
    Name:
    Jose-Carlos Gutierrez-Ramos
     
    Title:
    President


    Get the next $TBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TBIO

    DatePrice TargetRatingAnalyst
    8/4/2021$45.00 → $38.00Neutral
    Roth Capital
    8/3/2021$19.00 → $38.00Market Perform
    SVB Leerink
    8/3/2021Outperform → Market Perform
    William Blair
    7/26/2021$28.00 → $45.00Buy
    Roth Capital
    More analyst ratings

    $TBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

      New technology has potential to accelerate timelines for therapeutic research and drug development Telesis Bio Inc. (OTC:TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced a new license agreement with Regeneron Pharmaceuticals, Inc. to deploy Telesis Bio's revolutionary Gibson SOLA™ platform at its R&D core facilities. This will help Regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs. Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson SOLA platform has been shown to e

      5/28/25 9:00:00 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis

      Telesis Bio, a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced that it has entered into a convertible preferred stock purchase agreement (the Purchase Agreement) to sell shares of a new series of convertible preferred stock in a private placement. The financing was led by Novalis LifeSciences and Northpond Ventures and is expected to result in gross proceeds to the Company of up to approximately $21 million. The Company's recently launched proprietary next-generation enzymatic synthesis platform, Gibson SOLA™, allows customers to take full control of their nucleic acid supply-chain,

      3/18/25 9:00:00 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis

      SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bio's Gibson SOLA enzymatic reagent platform running on Beckman Coulter Life Sciences automation to ensures rapid, reliable, and highly scalable production of extremely high-fidelity DNA, empowering researchers to achieve greater productivity and innovation in a wide array of discovery applications. The collaboration integrates Telesis Bio's Gibson

      9/25/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Roth Capital reiterated coverage on Translate Bio with a new price target

      Roth Capital reiterated coverage of Translate Bio with a rating of Neutral and set a new price target of $38.00 from $45.00 previously

      8/4/21 10:08:32 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SVB Leerink reiterated coverage on Translate Bio with a new price target

      SVB Leerink reiterated coverage of Translate Bio with a rating of Market Perform and set a new price target of $38.00 from $19.00 previously

      8/3/21 11:37:09 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Translate Bio downgraded by William Blair

      William Blair downgraded Translate Bio from Outperform to Market Perform

      8/3/21 11:20:22 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Krueger Todd was granted 8,390 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      7/26/24 4:07:04 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Golub Steven J was granted 8,390 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      7/26/24 4:06:35 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Hlavinka Sarah E. was granted 8,390 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      7/26/24 4:06:03 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Telesis Bio Inc.

      SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)

      11/8/24 8:23:25 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Telesis Bio Inc.

      SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)

      11/6/24 4:50:27 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Telesis Bio Inc.

      SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)

      11/6/24 4:05:27 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Telesis Bio Reports Second Quarter and First Half 2024 Financial Results

      SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, today announced financial results for the second quarter and first half of 2024. Highlights Gibson SOLA – the Company continues to advance its Gibson SOLA reagent platform that enables on-premises automated overnight synthesis of high-fidelity long DNA and mRNA on a variety of liquid handling platforms. The Company's presentation "Enhancing Therapeutic Protein Production with Gibson SOLA Enzymatic DNA Assembly: Pioneeri

      8/7/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments
    • Telesis Bio Appoints William J. Kullback Chief Financial Officer

      SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023. As CFO, Kullback will be responsible for the Company's financial planning and analysis, accounting, internal audit, tax, and treasury functions. "Bill's deep industry knowledge, operational expertise, and extensive financial experience make him ideally positioned to help lead us through the next phase of the Company's growth," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. "We are thrilled to welcome Bill to our team and excited to have another lead

      8/29/23 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Financials

    Live finance-specific insights

    See more
    • Telesis Bio Reports First Quarter 2024 Financial Results

      SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the first quarter of 2024.  In discussing results, recently appointed President and CEO Eric Esser said, "I am pleased with our performance as we execute against our strategy to focus on Gibson SOLA and BioXp mRNA solutions. Our BioXp mRNA offerings continue to gain traction and are delivering real improvements in speed and simplicity to our customers in their discovery workflows. I'm also excited abo

      5/9/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results

      SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® kit sales, expanding gross margin and reduced operating expense. In discussing the results, Todd R. Nelson Ph.D., Founder and CEO of Telesis Bio said, "I'm pleased with our operating execution in a challenging macro environment during 2023. Our company experienced record BioXp kits sales and expanding gross margin aga

      3/28/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Reports Third Quarter 2023 Financial Results

      SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. "This quarter, we continued to drive adoption of our instruments and kits, make progress against important collaborations, advance our mRNA strategy, and strengthen both our Board of Directors and Management Team," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. Highlights Strengthened board of directors and management team: Appointed Greg Herrema, Senior Advisor to Novalis LifeSciences to the Telesis Bio board of directors in October 2023. Mr. Herrema's distinguished car

      11/13/23 4:22:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Telesis Bio Inc.

      15-12G - Telesis Bio Inc. (0001850079) (Filer)

      1/14/25 4:35:26 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form EFFECT filed by Telesis Bio Inc.

      EFFECT - Telesis Bio Inc. (0001850079) (Filer)

      1/7/25 12:15:02 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form EFFECT filed by Telesis Bio Inc.

      EFFECT - Telesis Bio Inc. (0001850079) (Filer)

      1/7/25 12:15:03 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials